Recent advances in proteomics technologies provide tremendous opportunities for biomarker-related clinical applications; however, the distinctive characteristics of human biofluids such as the high dynamic range in protein abundances and extreme complexity of the proteomes present tremendous challenges. In this review we summarize recent advances in LC-MS-based proteomics profiling and its applications in clinical proteomics as well as discuss the major challenges associated with implementing these technologies for more effective candidate biomarker discovery. Developments in immunoaffinity depletion and various fractionation approaches in combination with substantial improvements in LC-MS platforms have enabled the plasma proteome to be profiled with considerably greater dynamic range of coverage, allowing many proteins at low ng/ml levels to be confidently identified. Despite these significant advances and efforts, major challenges associated with the dynamic range of measurements and extent of proteome coverage, confidence of peptide/protein identifications, quantitation accuracy, analysis throughput, and the robustness of present instrumentation must be addressed before a proteomics profiling platform suitable for efficient clinical applications can be routinely implemented.
Advances in MS technologies, high resolution liquid phase separations, and informatics/bioinformatics for large scale data analysis have made MS-based proteomics an indispensable research tool with the potential to broadly impact biology and laboratory medicine (1) . In particular, proteomics technologies have been increasingly applied to the study of disease-related clinical samples (e.g. human blood serum/ plasma, proximal fluids, and disease tissues) for the purposes of identifying novel disease-specific protein biomarkers, gaining better understandings of disease processes, and discovering novel protein targets for therapeutic interventions and drug developments (2) .
Proteomics-based candidate biomarker discovery efforts have recently gained significant attention due to the power of these technologies for analyzing complex protein mixtures and their potential for identifying novel markers indicative of disease. It is widely believed that many complex human diseases, including cancers, might be more effectively cured if specific disease biomarkers were available to enable detection and treatment at very early stages of disease (3) . Despite noteworthy efforts, only a handful of cancer biomarkers have been approved by the United States Food and Drug Administration (FDA) 1 for clinical use, with the majority of these being protein biomarkers (4) . Although existing markers play a significant role in screening, monitoring, and staging, effective biomarkers are not currently available for most cancers and are generally nonexistent for early detection (3) . Therefore, there is a clear need for applying advanced technologies such as these based on proteomics in the quest for novel candidate clinical biomarkers.
Although widely speculated that advances in genomics and proteomics would alter the landscape of clinical biomarker discovery and validation, the declining trend of new FDAapproved biomarkers reported over the last decade (5) highlights the magnitude of the challenges associated with human clinical samples and validation of candidate biomarkers. Contributing to these challenges are the substantial complexity of the human proteome and the heterogeneity of the human population, both of which make the search for biomarkers from either biofluids or disease tissues a daunting task. As a result of the heterogeneous nature of humans and the complexity of diseases, e.g. cancers, a panel of biomarkers rather than a single marker may be required to achieve the high sensitivity and specificity required for clinical applications (3) . Proteomics technologies offer significant potential for discovering such marker panels.
Many different technologies have been applied for biomarker discovery and other clinical applications, including twodimensional (2D) gel-electrophoresis (6), LC-MS, and proteinand antibody-based microarrays (7) (8) (9) . LC-MS-or tandem MS (MS/MS)-based proteomics technologies offer highly sensitive analytical capabilities and a relatively large dynamic range of detection and have increasingly become the method of choice for in depth profiling of complex protein mixtures (1) . In addition, the relatively high throughput of LC-MS technologies is amenable to clinical applications that involve human biofluids and disease tissues. The application of LC-MS/MS for human biofluid protein profiling was initiated by the first global shotgun proteomics study of human plasma/serum published in 2002 by Adkins et al. (10) . An explosion of LC-MS-based applications in human plasma/serum and various biofluids soon followed due to the tremendous interest in identifying disease-related proteins (11, 12) . Various depletion/fractionation/enrichment techniques have been developed along the way and coupled to LC-MS to increase coverage of the biofluid proteomes (13) .
Human blood serum/plasma remains the most commonly used clinical sample to date for proteomics applications because it may include specific biomarkers for virtually all human diseases due to its either direct or indirect interaction with the entire cell complement of the body, i.e. tissue-specific proteins may be released into the blood stream upon cell damage or cell death. Additionally serum/plasma can be readily obtained by clinical sampling. However, the magnitude of the previously mentioned challenges associated with human clinical samples coupled with the anticipation that potential biomarkers of interest could be present at extremely low concentrations in plasma has raised doubts as to whether disease biomarkers can be accurately detected or identified from plasma using a proteomics approach. As a result, analysis of various other biofluids/tissues has gained increasing attention. Due to their proximity to the source of disease or perturbation in the body, tissues (14) and various biofluids such as cerebrospinal fluid (15) , bronchoalveolar lavage fluid (16) , synovial fluid (17) , nipple aspirate fluid (18) , saliva (19) , and urine (20) are believed to provide a more focused pool of potential biomarkers of interest. In addition, tumor interstitial fluids have also been reported as a novel source for proteomics biomarker and therapeutic target discovery (21) , offering a promising alternative to direct tissue analysis. In the following review, we highlight LC-MS-based proteomics profiling for clinical applications by summarizing recent advances as well as the major challenges facing this technology for more effective candidate biomarker discovery.
CHALLENGES AND REQUIREMENTS FOR DESIGNING A ROBUST LC-MS DISCOVERY PLATFORM
The distinctive nature of human biofluid proteomes, in particular the serum/plasma proteome, presents significant challenges for current analytical technologies aimed at quantitative protein profiling and biomarker discovery. First, the serum/plasma protein content is dominated by several very abundant proteins (i.e. the 22 most abundant proteins represent ϳ99% of the total protein mass in plasma) yet at the same time presents an extraordinary dynamic range (Ͼ10 orders of magnitude) in protein concentrations that begins with serum albumin at ϳ45 mg/ml and extends to cytokines (and potentially many disease-related proteins) at around 1-10 pg/ml or lower (5) . Second, the serum/plasma proteome presents tremendous biological complexity as a result of tissue "leakage" proteins from the entire body, complex post-translational protein modifications such as glycosylation, and the existence of various forms (i.e. splice variants, proteolytic products, and the tremendous variability in the immunoglobulin class) for each expressed gene. Finally the substantial genetic and non-genetic biological variability of human clinical samples contributes significantly to the overall analytical challenge.
Despite significant recent advances, major challenges remain to prevent routine implementation of an LC-MS protein profiling platform suitable for efficient biomarker discovery (Table I) . To effectively address these challenges, a protein profiling platform suitable for biomarker discovery and clinical applications must provide at the very minimum 1) overall high dynamic range of measurements and extensive coverage of the proteome for effective detection of low abundance proteins, 2) highly confident and specific protein identifications, 
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3) accurate quantitation of relative protein abundances across many clinical samples, and 4) high throughput capable of analyzing large numbers of clinical samples to provide sufficient statistical power needed to address biological variability. In addition, the platform, including both sample processing and LC-MS instrumentation, must be robust and include efficient informatics software capabilities for data mining and statistical analyses. Currently there is a broad consensus that no existing platform meets all of these requirements for effective biomarker discovery. Fig. 1 shows a component-based diagram of an LC-MS protein profiling platform. Note that such a platform is not based on a single instrument but rather on a compilation of current technologies to achieve high dynamic range quantitative proteome profiling for clinical samples. A key performance factor of any such platform is the overall dynamic range of detection and extent of proteome coverage, which in turn dictates its ability to detect low abundance proteins. Many disease-specific proteins in plasma/serum are anticipated to be present at very low levels (ng/ml or even lower), e.g. within the same range as current FDA-approved markers such as prostate-specific antigen (0.01-100 ng/ml) and Troponin-T (0.02-100 ng/ml). This is particularly obvious for cancer markers of early detection where tumor size is very small (millimeter size), and cancer-specific proteins in plasma may present at pg/ml or lower levels. This overall dynamic range presents a tremendous challenge for any MS-based technology. The achievable dynamic range or proteome coverage for a platform depends on the peak capacity (the number of chromatographic peaks that can be fit into the length of separation) of the on-line LC separations prior to MS measurements, the dynamic range of the MS instrumentation, and the efficiency of sample enrichment or fractionation steps at both protein and peptide levels prior to LC-MS analyses. Analysis throughput inevitably determines the size of any clinical study sample set and largely depends on factors such as automation of each platform component, LC-MS analysis duty cycle, and the extent of prefractionation prior to LC-MS analysis. Although the application of more extensive fractionation can lead to a higher dynamic range of detection, the overall throughput can be severely reduced. Other key performance factors are the confidence of protein identifications and the quantitative accuracy, which determine the ability of the platform to confidently identify a potential biomarker based on the abundance differences between healthy and diseased conditions. Both the reproducibility of sample processing/fractionation prior to LC-MS and the LC-MS instrumentation will contribute to the accuracy of quantitation.
ADVANCES IN LC-MS TECHNOLOGIES
A high resolution LC (or LC/LC) separation coupled on line with MS is the central component of many proteomics platforms. Over the past decade, there have been significant advances in LC separations as well as in MS instrumentation and ESI. To date, the "bottom-up" proteomics strategy that combines high efficiency separations with MS to characterize highly complex peptide mixtures still accounts for the majority of proteomics measurements. This strategy relies on the identification of peptides sufficiently unique for protein identification. Protein mixtures from cellular lysates or biofluids are typically digested by trypsin (or other proteases) into polypeptides, which are then separated by capillary LC and analyzed by MS on line via an ESI interface. Peptide sequences are identified by using automated database searching algorithms such as SEQUEST (22) , MASCOT (23), or X!Tandem (24) to correlate experimental MS/MS spectra to theoretical mass spectra based on sequences in a given protein database for a specific organism. With the recent development of high speed 2D linear ion trap instruments, i.e. LTQ, the protein profiling coverage has been greatly enhanced compared with traditional three-dimensional ion trap systems (25) . When coupled with SCX fractionation either on line or off line (26, 27) , LC-MS/MS technologies now routinely allow for identification of thousands of proteins from complex mammalian tissues and cells. Although routinely used for peptide/protein identifications, data-dependent LC-MS/MS still has an inherent "undersampling" limitation whereby only a portion of the species observed in the survey MS scan is selected for fragmentation (28) .
To overcome the undersampling issue, our laboratory developed an accurate mass and time (AMT) tag approach that utilizes highly accurate mass measurements from a high resolution mass spectrometer (e.g. FTICR or TOF mass spectrometer) in conjunction with accurate elution time measurements from high resolution capillary LC separations to achieve high throughput proteome profiling without routine MS/MS measurements (29, 30) . The concept of this AMT tag approach is based on the principle that the accurate mass and time measurements will allow reliable peptide identifications by correlating the mass and time of detected peaks to a pre-established peptide AMT tag reference library for a particular biological system (e.g. plasma). With this approach, LC-MS/MS proteome analyses coupled with extensive fractionation only need to be performed once to create an effective reference database of peptide markers defined by accurate masses and elution times, i.e. AMT tags. The AMT tag database then serves as a comprehensive "look-up table" for subsequent higher throughput LC-MS analyses, allowing many peptides in each spectrum to be identified without MS/MS. Fig. 2 exemplifies an LC chromatogram and 2D display of ϳ2,800 peptides identified using the AMT tag strategy resulting from a single LC-FTICR analysis of a ProteomeLab TM IgY-12 depleted human plasma sample. The fact that application of the AMT tag approach obviates the need for routine MS/MS is particularly attractive in high throughput repeated analyses of similar samples (e.g. serum/ plasma) in clinical proteomics studies. We have recently demonstrated the application of the AMT tag approach coupled with 18 O labeling for quantitative profiling of the human plasma proteome in response to lipopolysaccharide administration (31) . The availability of commercial high performance mass spectrometers (e.g. ThermoElectron Finnigan LTQ-FT and LTQ-Orbitrap) will likely lead to an even broader range of applications based on this LC-MS-only approach for higher throughput peptide identifications.
As mentioned previously, the achievable dynamic range for the LC-MS platform depends significantly on the peak capacity of the on-line gradient reversed phase separations, the dynamic range of the MS system, and the efficiency and stability of the ESI interface. A single MS spectrum can provide a dynamic range of up to 10 3 for a high resolution instrument (e.g. FTICR), and one would expect to achieve a dynamic range of at least 10 5 by coupling this instrument to an on-line high resolution LC separation that provides a peak capacity of ϳ1,000. However, the observed dynamic range of measurements can be significantly reduced for complex biological samples such as human plasma due to the charge competition of co-eluting high abundance species, leading to ion suppression of the relatively low abundance species. Ion suppression is a particular issue when analyzing human biofluid samples as these samples are dominated by a handful of highly abundant proteins. Significant ion suppression will occur when peptides originating from low abundance proteins of interest co-elute with peptides originating from high abundance proteins, leading to the inability to detect the co-eluting low abundance peptides. Table II provides a summary of the relative proteome coverage and estimated dynamic ranges achieved by coupling high resolution reversed phase capillary LC separations with either MS/MS using an LTQ instrument or MS using a 9.4-tesla FTICR instrument. The enhanced coverage and dynamic ranges obtained by the removal of high abundance proteins and SCX fractionation are illustrated. All results shown in Table II are based on triplicate experiments that involved a pooled plasma sample from healthy subjects. The number of peptide identifications are reported with Ͼ95% confidence based on either a reversed database evaluation for MS/MS data (32) or a shifted database evaluation for the LC- FTICR   FIG. 2 . A typical LC-FTICR analysis of an IgY-12 depleted human plasma sample. A, the base peak chromatogram. B, a 2D display of ϳ2,800 identified species at the mass and NET space. The analysis was performed using a Bruker 9.4-tesla FTICR instrument coupled with an LC system equipped with a 150-m-inner diameter and 65-cm-long capillary column operated at 5,000 p.s.i. data 2 with all proteins identified using a minimum of two different peptides. As shown, the single LC-MS/MS analysis only identifies ϳ100 proteins with high confidence and provides a dynamic range of ϳ10 3 . With the removal of either the top six (MARS) or top 12 (IgY-12) abundant proteins, the overall dynamic range is enhanced to ϳ10
5 . LC-FTICR shows greater coverage for both peptide and protein identifications compared with LC-MS/MS, and the dynamic range is estimated to be similar to that observed for LC-MS/MS. (It should be noted that presently unassigned peptides probably include many more proteins.) When IgY-12 depletion and SCX fractionation are combined with LC-MS/MS, a dynamic range of 10 6 -10 7 can be achieved, allowing identification of nearly 500 proteins in plasma with high confidence including many at the low ng/ml level, and 2D LC-FTICR analyses would be expected to increase this by approximately another order of magnitude. Note, however, that this dynamic range still falls 3 orders of magnitude short for detecting pg/ml protein concentrations. In addition, it should be noted that not all the proteins within the estimated dynamic range will be detected due to the differences in digestion efficiency and ion suppression effects for different proteins/peptides within the complex sample.
One key area of recent advances in LC-MS technologies is the improvement associated with capillary LC instrumentation that provides enhanced peak capacities and dynamic range of detection needed to analyze clinical samples. These improvements have been achieved primarily through the use of very high pressure (10 -20 kp.s.i.), very small porous particles (3 m or less), smaller inner diameter columns (50-m inner diameter or less), nanoelectrospray interfaces, and relatively long columns and long gradients for separations (33) (34) (35) . For example, high efficiency separations with peak capacities of ϳ1,000 have been achieved by using 15-75-m-inner diameter and 85-cm-long capillary columns packed with 3-m C 18 -bonded silica particles operated at 10 kp.s.i. By using smaller inner diameter columns (e.g. 15 m) (34), the sensitivity of the system continues to increase inversely as the mobile phase flow rates drop to as low as 20 nl/min, demonstrating the advantages of ESI-MS analyses at very low liquid flow rates (36, 37) . More recently, the use of 20 kp.s.i. capillary LC columns packed with 1.4 -3-m porous C 18 -bonded silica particles has been demonstrated to provide chromatographic peak capacities of 1,000 -1,500 for complex peptide and metabolite mixtures (35) . Although these very high pressure systems present technical challenges for robust automated op-
TABLE II The proteome coverage and estimated dynamic range offered by current LC-MS technologies
A pooled reference plasma sample from healthy individuals was used for this evaluation. A prepacked 4.6 ϫ 50-mm (loading capacity, 15 l of plasma) MARS affinity column (Agilent, Palo Alto, CA) and a 7 ϫ 52-mm (loading capacity, 25 l of plasma) ProteomeLab IgY-12 affinity column (Beckman Coulter, Fullerton, CA) were used for the depletion of high abundance proteins. For each method, the samples were processed in triplicate and individually analyzed using a 150-m-inner diameter and 65-cm-long column coupled with either a Finnigan LTQ system (MS/MS) or a Bruker 9.4-tesla FTICR instrument. 10 and 5 g of peptide samples were loaded for each LC-MS/MS and LC-FTICR analyses, respectively. 300 g of peptides were used for each SCX fractionation. The LC and SCX operations were the same as described previously (31) . Peptides were filtered with a confidence level Ͼ95% based on reversed database evaluation (32) , and proteins were identified with at least two different peptides. ALS, acid-labile subunit; vWF, von Willebrand factor; SAA, serum amyloid A; CRP, C-reactive protein; HGFA, hepatocyte growth factor activator; MSF, megakaryocyte-stimulating factor; EGFR, epidermal growth factor receptor; APOC2, apolipoprotein C-II; B2M, ␤2-microglobulin; NAP1L1, nucleosome assembly protein 1-like1; MMP2, matrix metallopeptidase 2; 1D, onedimensional. We note that more relaxed indentification criteria would considerably expand the numbers of peptides and proteins identified by all approaches. Given the tremendous dynamic range of protein abundances and the extraordinary complexity of human biofluid proteomes, many different fractionation techniques have been developed and applied in a multidimensional fashion to enhance dynamic range of detection and improve proteome coverage (13) . Multicomponent immunoaffinity removal of highly abundant proteins in human plasma/serum (38, 39) has increasingly become the method of choice for prefractionating human plasma samples due to the high specificity, efficacy, and ease of coupling to other fractionation techniques. As shown in Table II , coupling the immunoaffinity depletion step to LC-MS provides an additional 1-2 orders of magnitude increase in dynamic range, allowing for detection of more low abundance proteins by effectively increasing the sample loading; similar improvements were reported in other studies (40, 41) . Good reproducibility was demonstrated by performing immunoaffinity depletion with an automated LC system; however, some of the nontarget low abundance proteins have also been observed to bind to the columns but in a reproducible fashion (42) . A possible approach to counter this effect is to analyze both the flow-through and bound fractions in more of a "partitioning" method instead of a pure "depletion" approach (39) with the accompanying trade-off of an increased number of required analyses. A further enhancement to the platform dynamic range will stem from the continuous improvement of antibody-based microbead technologies that will allow for removal of more highly to moderately abundant proteins.
Methods
Several different techniques for protein-level fractionation have been applied to human plasma/serum proteome profiling, including common gel-based techniques (43, 44) , PF2D automated chromatofocusing/reversed phase LC (RPLC) (45) and other liquid chromatography-based separations (46), free-flow electrophoresis (41, 47) , and IEF (46, 48 -51) . IEF is a common fractionation technique that has been applied to plasma profiling at both peptide and protein levels. Various forms of liquid phase IEF techniques have been developed, including off-gel electrophoresis (48) , Rotofor (49) or MiniRotofor (46), microscale solution IEF (ZOOM) (50) , and a preparative multichannel electrolyte system (51) . A common feature of these systems is the multiple tandem electrode chambers used to partition complex protein samples. IPG IEF followed by in-gel digestion has also been used for plasma protein fractionation prior to LC-MS/MS (52) . A number of recent large scale proteome profiling studies have combined different protein-and peptide-level fractionation techniques (e.g. PF2D (45) , SCX/RPLC (54), free flow electrophoresis-IEF/ RPLC (47), ZOOM/SDS-PAGE (50) , and Rotofor/RPLC/SDS-PAGE (49) protein fractionation) with peptide-level LC-MS/MS analyses to achieve more comprehensive coverage of the plasma proteome.
An alternative to plasma protein fractionation is to specifically enrich functional "subproteomes" such as the glycoproteome or the cysteinyl subproteome by using chemical tagging or capture agents; this significantly reduces overall sample complexity and enhances detection of low abundance proteins. For example, we have recently demonstrated a simple procedure for effectively enriching cysteinyl peptides from complex proteomes (including human biofluids (55)) that provides significantly improved proteome coverage when used as a peptide-level fractionation technique (27) . Additionally hydrazine chemistry can be applied to specifically enrich Nlinked glycopeptides (56, 57) , and multilectin affinity chromatography can be used to isolate and characterize glycoproteins from human plasma and serum samples (58) . Our laboratory has recently developed a strategy that combines immunoaffinity depletion and subsequent chemical fractionation based on cysteinyl peptide and N-glycoprotein captures with 2D LC-MS/MS for in depth plasma profiling (Fig. 3) (59) . Application of this "divide-and-conquer" strategy to trauma patient plasma samples resulted in confident identification of ϳ1,500 different proteins (with a minimum of two peptides per protein; ϳ99.5% confidence level based on reversed database evaluation) and illustrated an overall dynamic range of detection of Ͼ10 7 (low ng/ml concentrations for six identified low abundance proteins were verified by ELISA).
ANALYSIS THROUGHPUT
Although integration of extensive multidimensional fractionation/separations with MS greatly increases the overall proteomics analysis dynamic range and the extent of proteome coverage, this general approach suffers from the limitation of very low throughput. To date, most reports involving extensive fractionation have been limited to small scale studies of one or two pooled clinical samples rather than larger scale quantitative studies. The development of more effective depletion/fractionation strategies and improved LC-MS platforms will most likely reduce the total number of fractions necessary for the detection of low abundance and clinically relevant proteins and thus provide higher throughput.
Several recent technology developments hold potential for greatly enhancing the overall analysis throughput of clinical samples. The first is the development of very fast LC separations for proteomics analyses. Current automated LC-MS proteomics platforms typically involve LC separations with gradients of 100 min or longer, which limits throughput to ϳ10 sample analyses per day per MS instrument. Several reports have explored the use of smaller particle-packed columns or monolithic columns for fast LC separations (10 min or less) as well as multiplex column systems to significantly improve the throughput (60, 61) . However, it is unclear whether sufficient separation power can be achieved with these fast liquid phase separations because the increase in the solvent gradient speed can degrade the separation peak capacity (60), which in turn reduces the overall dynamic range of detection. Other strategies for achieving robust fast separations include liquid phase chromatographic and electrophoretic separations on a microfluidic chip platform (62) (63) (64) . Such chip-based separation devices also have the advantage of providing better robustness, reliability, and ease of operation.
Very fast (millisecond scale) gas phase separations based on ion mobility spectrometry (IMS; a separation method that is somewhat analogous to electrophoresis in the gas phase) are another powerful alternative to liquid phase separations for significant improvement in throughput. At its simplest, an IMS stage consists of a drift tube filled with a non-reactive gas (commonly helium or N 2 ) and a uniform electric field established along the axis of separation. Mixtures of peptides, proteins, or small molecules are separated by their gas phase cross-sections (size) in addition to charge, and knowledge of their mobility provides another separation dimension to aid in identification.
The power of IMS has been advanced by several recent technical developments. IMS coupled with a TOF MS platform and combinatorial libraries (65) has been recently demonstrated for analysis of proteolytic digests (66) . Because an IMS separation typically requires 1-100 ms and has a resolving power of 50 -200, a single species IMS peak exits the drift tube over a ϳ0.1-1-ms period. Generation of a typical TOF MS spectrum requires ϳ30 -100 s, which allows multiple mass spectra to be obtained during the "elution" of an IMS peak. More recently, LC has been coupled to IMS-TOF MS via an ESI interface, providing 2D separations prior to MS analysis (67) . Despite enormous potential for high throughput analyses of complex samples, the application of IMS-TOF MS has been limited by low sensitivity due to ion losses at the IMS-MS interface; however, the recent implementation of FIG. 3 . Schematic representation of a chemical fractionation strategy applied to the plasma proteome characterization. High abundance proteins were first removed using immunoaffinity subtraction. The resulting less abundant proteins were split and subjected to solid phase cysteinyl peptide and N-glycoprotein captures independently. Non-cysteinyl peptides and non-glycopeptides generated at the same time were also collected. All four different peptide populations were then fractionated by SCX, and each fraction was analyzed by capillary LC-MS/MS. PNGase F, peptide-N-glycosidase F (59).
electrodynamic ion funnels at both the ESI-IMS and IMS-TOF MS interfaces has significantly improved the sensitivity of the overall LC-ESI-IMS-TOF MS platform (Fig. 4) (68) such that the sensitivity is now comparable to that of a commercial ESI-MS instrument. Although still in the development stage, the very fast separation speed and potential high dynamic range of measurements offered by the 2D liquid phase-gas phase separations make LC-ESI-IMS-TOF MS an attractive and practical platform for high throughput clinical applications.
CONFIDENCE OF PEPTIDE/PROTEIN IDENTIFICATIONS
One of the challenges associated with MS/MS-based proteome profiling is how to assess the confidence levels of peptide and protein identifications that result from automated database searching. It is recognized that a significant portion of the protein identifications in previously published proteomics datasets of human plasma are likely comprised of false positive identifications (32, 69 -71) . For example, four different plasma proteomics datasets that originated from different methodologies were combined into a list that included 1,175 non-redundant proteins; however, only 46 of these non-redundant proteins (ϳ4%) were observed across all four studies (70) . This surprisingly low overlap suggests the potential for a very large number of false protein identifications. In a plasma profiling study using nanoscale LC-MS/MS, Shen et al. (69) reported a nearly 2-fold difference in the number of identified proteins (ranging from 800 to 1,600) depending on which set of previously published criteria were used to filter the data. This criteria-dependent difference illustrates the need for more detailed statistical evaluations to ensure high confidence protein identifications.
To address the issue of false peptide identifications, we recently performed a probability-based evaluation of peptide identifications derived from LC-MS/MS and SEQUEST analysis in which selected human proteomes, including human plasma, were searched against a sequence-reversed human protein database (32) similar to a previous report applying the reversed database strategy to the yeast proteome (72) . The reversed protein database was created by reversing the order of amino acid sequences for each protein (the carboxyl terminus becomes the amino terminus and vice versa) in the original human protein database. This approach assumes that the numbers of false positives that arise from "random" hits should be the same for both the normal database and the reversed database because the reversed database is identical in number of protein entries, protein size, and distribution of amino acids to the normal database. fully tryptic) from a human plasma sample identified by searching the normal (solid line) and reversed (dashed line) databases. The Xcorr distribution allows an estimated confidence level for any given Xcorr bin as well as the overall false positive rate for a given Xcorr cutoff to be calculated by dividing the area beneath the dashed line (reversed database hits) by the area beneath the solid line (normal database hits) for a given Xcorr range. This study also revealed the high false positive rates for plasma/serum peptide/protein identifications in several previously published studies (10, 69, 70, 73, 74) . For example, ϳ30% false positives were observed when the often cited Washburn et al. (75) filtering criteria were applied to human plasma. Thus, filtering criteria that provided overall Ͼ95% confidence at the unique peptide level for both human cell lines and human plasma were proposed. When identical filtering criteria were used, the observed false positive rates of peptide identifications for human plasma were significantly higher than those for the human cell lines, suggesting that the false positive rates are significantly dependent upon sample characteristics, particularly the number of proteins found within the detectable dynamic range for different samples. Additionally Xie and Griffin (76) reported the increased potential for false positive identifications for the 2D linear ion trap (LTQ) when compared with a traditional threedimensional ion trap (LCQ) instrument, and more stringent filtering criteria are required for LTQ compared with LCQ to minimize false positive identifications. These results suggest that peptide/protein identification confidence levels not only depend on sample characteristics but also on components of the LC-MS platform.
Table III illustrates differences in filtering criteria stringency by comparing peptide/protein identification results from the same plasma MS/MS dataset (obtained from a recent profiling study using trauma patient plasma samples (59) ) that was filtered using three different sets of criteria (77, 78) . As shown, the reversed database filtering criteria generated the smallest number of peptide and protein identifications, consistent with the significantly lower percentage of false positive identifications (ϳ4%), whereas the Human Proteome Organization (HUPO) plasma proteome project-recommended criteria (77) and the criteria recently reported by Hood et al. (78) . generated nearly ϳ25 and ϳ66% false positives at the peptide level, respectively. The comparison shows that the number of peptide/protein identifications from an individual protein profiling study could be easily inflated if a statistical evaluation of false positives was not performed.
A similar observation was recently reported for proteins identified from data acquired on different instruments from 18 laboratories as part of the large scale HUPO plasma proteome collaborative study (77) . Application of a rigorous statistical approach that used multiple hypothesis-testing techniques and took into account the length of coding regions in genes reduced the initial list of 9,504 proteins (of which 3,020 were identified with two or more peptides) to 889 proteins (containing both multipeptide and single peptide protein identifications) identified with a confidence level of at least 95% (71) . Interestingly this length-dependent statistical approach was applied to reanalyze one of our previously published datasets (69) and resulted in 1,073 proteins using the HUPO criteria and 433 proteins using the Ͼ95% confidence length-dependent statistics (71) . Similarly a ϳ2-fold difference in protein identifications between the reversed database filtering results and the HUPO criteria (Table  III) was observed, suggesting similar performance between the length-dependent statistical approach and reversed database filtering with Ͼ95% confidence.
PeptideProphet provides another independent statistical model for evaluating potential false positive peptide identifications. The model utilizes the expectation maximum algorithm to derive a mixture of correct and incorrect peptide 
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assignments from the data (79) . This approach has been directly compared with the reversed database approach for analyzing the same dataset derived from human plasma (59) . Following filtering with reversed database criteria, 6,279 unique peptides were identified from this dataset with Ͼ95% confidence, whereas 6,341 unique peptides were identified by PeptideProphet using a minimum computed probability of 0.95. Approximately 95% of peptides were common between the two datasets, suggesting comparable results from these two statistical approaches. The use of ProteinProphet, another statistical model that computes the probability of the presence of proteins, addresses the issue of whether peptides are present in more than one entry in the protein database (protein redundancy problem) (80) . The list of identified peptides from both the PeptideProphet and the reversed database filtering approaches can serve as input for ProteinProphet to generate a list of non-redundant protein identifications. Several other statistical methods have been recently described for evaluating peptide assignments from MS/MS spectra (81) (82) (83) . Ideally universal acceptance of a statistical model that optimizes both sensitivity and specificity for confident peptide identifications from MS/MS spectra will allow cross-comparison of protein profiling results from different laboratories, which currently remains as an unresolved challenge.
Similar challenges exist for evaluating false positive identifications from MS-only approaches that utilize accurate mass measurements for peptide/protein identifications. The utility of accurate mass measurements initially was demonstrated in the "peptide mass fingerprinting" approach for protein identification in which a set of peptide fragments unique to each protein are created by digestion, and the mass of these peptide fragments is used as a "fingerprint" to identify the original protein (84 -86) . Thus far, this approach has been limited to simple protein mixtures or single proteins. The more recently reported AMT tag approach utilizes accurate LC retention time measurements in addition to accurate mass measurements to identify peptides and has been successfully applied to global proteome profiling, including the human plasma proteome (31, 87) . With the AMT tag approach, peptides are identified by matching LC-MS observed mass and normalized elution time (NET) features to AMT tags in the pre-established reference database (look-up table of peptides) with a given mass error and NET error tolerances (typically 1-5 ppm for mass and 1-3% for NET). The potential false positive identifications resulting from random matching of features to the reference database are indicated on histograms of mass error (the difference between observed mass and calculated mass for the matched peptide in the database) exemplified in 6 . A, mass error histograms of features detected from a single LC-FTICR dataset of a human plasma sample that matched to a human plasma AMT tag database using different levels of NET constraints. The LC separation time is normalized to a 0 -1 scale in NET. B, mass error histograms for features from the same dataset matching to a normal AMT tag database (gray circles) and to a shifted AMT tag database (black squares). Note, the black squares represent random matches to the 11 Da shifted AMT tag database.
base approach for evaluating the false positive rate in the AMT tag process. 2 As shown in Fig. 6B , an ϳ3% false positive rate for this human plasma dataset was estimated as the ratio of the area beneath the curve that represents matches to the shifted database (black squares) and the area beneath the curve that represents matches to the normal database within a Ϯ2 ppm window (gray circles). In addition to being used for direct identification in the MS-only approach, the accurate mass information also has been utilized for improving the confidence of peptide identifications by MS/MS through application of the new generation of LTQ-FT and LTQ-Orbitrap mass spectrometers (88, 89) . QUANTITATION 
STRATEGIES
The ability to quantitatively measure relative protein abundance differences between different clinical samples is essential for identifying candidate protein biomarkers; however, the vast majority of proteomics work related to biomarker discovery published to date has been qualitative, highlighting the need for more robust quantitative approaches for such applications. Our initial application for comparative proteome analysis of human plasma following lipopolysaccharide (LPS) administration involved a semiquantitative strategy based on the total number of peptide identifications per protein (peptide hits or spectrum count) (74) . In this study, standard SCX-LC-MS/MS analysis was performed at the 0-h time point (control) and a 9-h time point following LPS administration, and peptide hits were used to obtain a relative quantitative measure between the control and 9-h time point. Several known inflammatory response and acute phase proteins were observed to be up-regulated upon LPS administration. Several other studies have shown that this peptide hits approach can be used as a semiquantitative approach for initial screening when applied with proper controls and with adequate thresholds (90 -93) .
More recently, we have demonstrated 16 O/ 18 O labeling combined with the AMT tag strategy as an effective global quantitative approach for quantifying relative protein abundance differences in human plasma (31) . By incubating tryptic peptides in 18 O water (55, 94) in the presence of trypsin, the 18 O atoms are incorporated into the carboxyl terminus of tryptically cleaved peptides via a postdigestion trypsin-catalyzed oxygen exchange reaction. The 16 O/ 18 O-labeled peptide pairs provide a 4-Da mass difference (Fig. 7A) , which allows a high resolution mass spectrometer such as FTICR or TOF to effectively resolve the 16 O-and 18 O-labeled peptide pairs and accurately measure the relative abundances. The advantage is that all types of samples (e.g. tissues, cells, and biological fluids) can be effectively labeled using this simple and specific enzyme-catalyzed reaction. Fig. 7A shows a partial 2D display of detected peptide pairs in mass versus time dimensions. The 18 O/ 16 O-labeled peptides are readily visualized as co-eluting pairs (4 Da apart), and the abundance ratio can be precisely calculated for each 18 O/ 16 O pair. In this initial comparative analysis demonstration of two human plasma samples obtained from a healthy individual prior to (control) and following LPS administration, relative abundance differences between the two plasma samples were quantified for a total of 429 plasma proteins. Fig. 7B shows the normalized -fold changes in 429 quantified proteins and demon- 
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by on April 14, 2008 www.mcponline.org strates the significant changes in abundance for a set of proteins following LPS administration. The combined 16 O/ 18 O labeling-AMT tag strategy can also be easily coupled with subsequent peptide-level fractionation approaches such as cysteinyl peptide enrichment (55) and SCX fractionation.
Other stable isotope labeling methods based on relative peptide/protein abundance measurements include metabolic labeling (95) (96) (97) and chemical labeling of specific functional groups using reagents such as ICAT (98) and iTRAQ (isobaric tags for relative and absolute quantitation) (99, 100) have been routinely used for quantitative proteomics analysis. In clinical proteomics applications, these stable isotope labeling techniques are well suited for detecting accurate changes in pairwise comparisons provided the samples can be effectively labeled; however, it is often challenging to compare across a large number of clinical samples. One alternative to the use of these labeling techniques is the use of a labeled reference sample (often a pooled composite) that is spiked into each normally processed individual clinical sample that allows relative quantitation between each clinical sample and the reference sample and cross-comparison among the entire set of clinical samples. The 18 O labeling strategy is well suited for generating such a labeled reference sample as all other clinical samples can be processed with natural 16 O on the carboxyl termini without labeling; 16 O/ 18 O peptide pairs are formed after spiking the samples with the 18 O-labeled reference.
Alternatively "label-free" direct quantitation approaches hold interest because of greater flexibility for comparative analyses and simpler sample processing procedures compared with labeling approaches. The isotope labeling and label-free approaches are complementary, and each approach has different sources of variations. Several initial studies suggest that the use of normalized LC-MS peak intensities for detected peptides can be used to compare relative abundances between similar complex samples (101) (102) (103) . It has been demonstrated that abundance ratios of separate model proteins may be predicted to within ϳ20% in complex proteome digests by using measured peptide ion intensities obtained in LC-MS analyses (101) . Among the main challenges for label-free quantitation are the multiple issues that affect the usefulness of peptide peak intensities for relative quantitation, such as differences in electrospray ionization efficiencies among different peptides and different samples (37) , differences in the amount of sample injected in each analysis, and sample preparation reproducibility. These issues are often peptide-dependent, leading to observed disparity among relative abundances of different peptides originating from the same protein. The significant bias and ion suppression effects caused by charge competition (ionization bias) during ESI (104) are often considered a major limitation for accurate label-free quantitation. Recent studies have demonstrated substantial advantages for ESI-MS analyses at nanoflow regimes (Ͻ100 nl/min) afforded by narrower inner diameter capillary columns for separations (36, 37) . It is well demonstrated that smaller inner diameter columns with lower flow rates provide significantly higher sensitivity than larger inner diameter columns with higher flow rates (34) because of the significant improvements in both ionization and MS sampling efficiencies. Reversed phase packed nanoscale LC and monolithic nanoscale LC separations have been developed and coupled to ESI for improved ionization and quantitation (34, 105) . As ionization efficiencies are increased for nanoelectrospray, detection biases are decreased because undesired matrix effects and/or ion suppression effects are either reduced or eliminated (104 -106) , providing the basis for improved quantitation. With further improvements to the robustness of these nano-LC-ESI-MS systems, label-free quantitation may be widely applied in clinical applications.
Another challenge for quantitative clinical proteomics applications is the variability introduced during multiple steps of sample processing. With continued development of cleanup products for more consistent performance and automated sample processing, such reproducibility issues may be minimized, leading to further improvements in quantitation when applying either the stable isotope labeling or label-free approaches.
IMPLICATIONS OF HUMAN HETEROGENEITY IN CLINICAL PROTEOMICS STUDIES
The ability to identify disease-specific differences by using a proteomics approach relies on multiple factors integral to the overall analysis pipeline. For example, when performing peptide-level measurements, achieving high peptide identification quality is a prerequisite for assuring confidence in all other downstream parameters (i.e. confidence in both protein identification and quantitation), whereas the ability to quantify differences between any two samples largely depends on the reproducibility of the overall platform. Due to inherent variations that stem from sample preparation and instrument analysis, technical replicates are often performed to evaluate and minimize technical variability arising from the overall analysis pipeline. Technical variability will be minimized as technologies continue to mature, and platforms will likely become more robust and reproducible; however, biological variability within the same comparative groups remains as a challenge for identifying real differences between different conditions. Although ideally one would like to either control or minimize such biological variability by utilizing more controlled model systems such as cell cultures, an in vitro model system, or even inbred mouse strains, this is not always possible. Most clinical studies are based on "real world" human clinical samples where inherent human individual heterogeneity makes discovery efforts more difficult. The human heterogeneity challenge in proteomics studies stems from the high probability that two equally "healthy" individuals will have overall significantly different individual protein abundance levels when sampled at any given time. This heterogeneity can be due to individual genetic variability (i.e. gender, race, etc.) and/or to contributing environmental factors such as diet, overall health, detrimental environmental exposures, etc. The complexity of human diseases presents another degree of challenge. For example, in human cancer, each tumor type typically consists of a number of subtypes that differ with regard to their spectrum of genetic alterations (107) . Therefore, a potential candidate biomarker of disease may be elevated only in a certain percentage of the pool of disease patients.
The implications of human heterogeneity in the context of LC-MS-based proteomics experiments centers mostly on the measured quantitative values for peptide/protein identifications. Fig. 8 shows an initial evaluation of the technical variation and biological variations of human and mouse plasma samples based on the Pearson correlation of the identified peptide intensities between any two individual samples. The technical replicate results ( Fig. 8A ; nine individually processed samples from one pooled reference plasma) show overall good correlation (0.94 Ϯ 0.02), which suggests relatively good reproducibility of the overall analytical platform. The increased variation among human subjects (Fig. 8B) appears obvious on the basis of significantly reduced average correlation coefficients (0.85 Ϯ 0.06) compared with the technical replicate results; whereas mouse plasma samples (Fig. 8C) show only slightly reduced correlation (0.92 Ϯ 0.05), which suggests relatively small biological variation in these inbred mouse models. Such large variations observed among different healthy control subjects present a challenge for identifying disease-specific differences. To address these challenges and increase the confidence of discovery results, it is essential for the discovery platform to be able to analyze a relatively large number of clinical samples in a high throughput manner to obtain sufficient statistical power.
Other proteomics studies have also described the effects of human heterogeneity in specific model systems. Hu et al. (15) performed a limited study that compared both intra-and interindividual variability of human cerebrospinal fluid samples obtained from six individuals. Specific proteins were observed to fluctuate over time with the same individual, but overall there was a higher concordance of interindividual results than across individuals. Interestingly results from measuring intraindividual protein levels suggested that certain proteins tended to fluctuate more than others, calling into question the effectiveness of using these proteins as potential disease markers. Other studies include a report by Zhan and Desiderio (108) that showed the heterogeneity in 2D gel electrophoresis human pituitary proteome analysis and an interesting review by Mann et al. (109) that overviewed the effects of genotypic and phenotypic variations in evaluations of the hemostatic proteome. They reported that "normal" pro-and anticoagulant concentrations were observed to vary significantly and influence downstream responses, demonstrating how heterogeneity in individual phenotypes should influence diagnosis and therapy for hemorrhagic and thrombotic diseases. 
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Designing experiments to minimize biological variability is imperative for clinical studies. One example is to analyze a serial sample set, i.e. plasma or biopsy tissue samples, from the same individual over a time course or disease progression; this in theory will alleviate a majority of heterogeneity effects, but such samples are traditionally more difficult to obtain in addition to the fact that most patients do not have a "control" blood or tissue sample in storage for comparison against a possible disease diagnosis. For most studies that use cross-sectional approaches, it is desirable to match the patients and controls in terms of age, sex, race, weight, and even diet if possible. A recent study reported the potential utility of pooling for reducing the effects of biological variation in microarray studies while retaining the accuracy of identifying differentially expressed genes when biological replicates are retained in the study design and providing the additional benefit of a great reduction in the total number of samples to be analyzed (110) . Such a strategy might be explored and extended to clinical proteomics studies.
A further implication in heterogeneity is the presence of protein isoforms, splice variants, specific amino acid mutations, proteolytic products, and other post-translational modifications that are likely present in individual samples but are most often not explicitly included as sequences in the searchable protein database. This exclusion makes it challenging for traditional LC-MS/MS-based bottom-up approaches to identify such modified proteins and is possibly one of the main reasons that a large percentage of MS/MS spectra in clinical analyses remain unidentified. The identification of amino acidspecific post-translational modifications (e.g. phosphorylation, glycosylation, glycation, nitration, oxidation, and deamination) challenges MS/MS-based approaches due to the vast variety of possible modifications and the potential high false positive rates that originate from database searching. Because it is recognized that many protein biomarkers may be specific protein isoforms or modified proteins, further technical developments for more effective identification and quantitation of protein isoforms and modifications would be greatly desirable.
As an alternative to identifying protein isoforms and modifications, intact protein-level separations can be used to separate different protein isoforms on the basis of their different masses or other properties. The ability to use 2D gel electrophoresis for resolving different isoforms and monitoring their abundance changes has been well documented (111) . The recently developed multidimensional intact protein analysis system (IPAS) separates intact proteins on the basis of charge, hydrophobicity, and molecular mass; quantitation is achieved by protein tagging with fluorophores (43) . The potential for revealing different protein isoforms and specific protein cleavage products in human plasma/serum also has been demonstrated (49) . The advantages offered by intact protein analysis complements the bottom-up proteomics approaches, and better integration of these two approaches may lead to more effective biomarker discovery.
TARGETED PROTEOMICS APPROACHES
The majority of proteomics applications in the search for candidate biomarkers to date have been focused on global proteome characterization focused on identifying multiple protein differences (candidate biomarkers) that correlate with specific human diseases; however, as discussed previously, there are many challenges associated with applying such a strategy to the discovery of low abundance candidate marker proteins. An alternative strategy for biomarker discovery that complements global profiling is the targeted proteomics approach that involves quantitative MS to measure a hypothesis-generated list of candidates (112) . The targeted proteomics strategy often provides greater sensitivity and allows for detection of low abundance candidate proteins. Anderson and Hunter (113) recently demonstrated the use of peptide multiple reaction monitoring (MRM) for quantitative assaying of major plasma proteins. Such MRM assays provide great specificity for peptide/ protein identifications and relatively good precision for quantitation. Additionally MRM can provide a rapid and specific platform for biomarker validation, particularly when coupled with specific enrichment techniques such as the recently published SISCAPA (Stable Isotope Standards and Capture by Anti-Peptide Antibodies) method for enriching target peptides using anti-peptide antibodies (114) . Activitybased protein profiling is another strategy that uses chemical probes for tagging, enriching, and isolating a specific subset of physiologically important proteins on the basis of enzymatic activity (115, 116) . Coupling such strategies with LC-MS holds potential for eliminating many issues related to the dynamic range of protein abundance.
A continuing issue for current LC-MS-based profiling approaches is that many of the detected species or features from LC-MS and LC-MS/MS analyses remain unidentified. Based on our experience, ϳ80% of MS/MS spectra on average are not confidently identified via database searching, and more than 50% of LC-FTICR-detected features remain unidentified by the AMT tag approach. Present informatics tools and statistical algorithms have been able to utilize intensity information of these unidentified features to identify "interesting" features as potential biomarkers for specific diseases; effectively targeting these interesting features using data-directed or targeted MS/MS approaches is of current interest. One of the informatics challenges associated with identifying these features concerns different post-translational modifications. Current commercial mass spectrometers such as the LTQ offer a targeted MS/MS capability based on the selection of a list of m/z values. Developing an advanced targeted MS/MS approach (117) that incorporates "smart selection" of the targets and different, but complementary fragmentation techniques will be an integral component for an effective LC-MS profiling platform suitable for clinical applications.
CONCLUSIONS AND PERSPECTIVES
The amount of effort placed into the development and application of effective proteomics profiling of serum/plasma and other clinical samples has increased tremendously over the last several years. With the emergence of more effective LC-MS technologies and the variety of fractionation approaches, the number of proteins detectable in human plasma by global profiling has been greatly expanded (e.g. 889 proteins with Ͼ95% confidence reported in the recent HUPO study and 1,494 proteins with Ͼ99% confidence, including confident identification of many low ng/ml level plasma proteins, in our recent study (59) ). Although this level of detection still falls short of the 10 orders of magnitude in dynamic range that encompasses plasma protein abundances, it still offers significant potential for the discovery of novel candidate biomarkers from clinical plasma/serum samples.
Currently there is no single platform that represents the "best" technology for such discovery applications, and integration of multiple technologies is often required for detection and quantitation of low abundance proteins. The need for improved reproducibility, throughput, dynamic range, and quantitation will continue to drive technology development and improvement efforts. Importantly several new technological developments such as fast LC separations, gas phase IMS separations, and high efficiency nano-ESI interfaces presently appear promising for future discovery platforms and applications. With improvements in quantitation accuracy, throughput, and robustness, the LC-MS protein profiling platform may eventually become a powerful tool for clinical diagnostic testing that provides simultaneous measurements of a large number of clinically relevant analytes.
An important component of any integrated profiling platform not previously discussed is the informatics and statistical analysis. The development of more effective software packages will be essential for processing the large number of LC-MS datasets, which may include peak (or feature) detection, run-to-run feature alignment, intensity normalization, feature matching to the database, and statistical analysis to generate a list of high confidence potential candidates.
Finally due to the complexity of large scale clinical proteomics studies, collaborative efforts from multiple laboratories with different platforms may be required for benchmarking and better cross-validation of the discovery results and eliminating potential biases introduced into any given platform. This implies that a common set of standards is needed so that platform performance in different laboratories may be readily compared and large scale proteomics datasets can be effectively exchanged and shared. 
